{
  "symbol": "UNH",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.203,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.179
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 26,286 $ 25,427 Short-term investments 5,037 4,201 Accounts receivable, net 23,115 21,276 Other current receivables, net 26,762 17,694 Assets under management 3,414 3,755 Prepaid expenses and other current assets 7,424 6,084 Total current assets 92,038 78,437 Long-term investments 46,113 47,609 Property, equipment and capitalized software, net 9,801 11,450 Goodwill 105,436 103,732 Other intangible assets, net 14,729 15,194 Other assets 17,939 17,298 Total assets $ 286,056 $ 273,720 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 32,547 $ 32,395 Accounts payable and accrued liabilities 30,886 31,958 Short-term borrowings and current maturities of long-term debt 11,371 4,274 Unearned revenues 2,572 3,355 Other current liabilities 27,294 27,072 Total current liabilities 104,670 99,054 Long-term debt, less current maturities 63,727 58,263 Deferred income taxes 3,631 3,021 Other liabilities 14,794 14,463 Total liabilities 186,822 174,801 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,558 4,498 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 921 and 924 issued and outstanding 9 9 Additional paid-in capital 373 \u2014 Retained earnings 92,400 95,774 Accumulated other comprehensive loss ( 3,423 ) ( 7,027 ) Nonredeemable noncontrolling interests 5,317 5,665 Total equity 94,676 94,421 Total liabilities, redeemable noncontrolling interests and equity $ 286,056 $ 273,720 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2024 2023 2024 2023 Revenues: Premiums $ 76,897 $ 72,474 $ 154,885 $ 145,260 Products 12,211 10,651 24,120 20,918 Services 8,750 8,663 17,638 16,743 Investment and other income 997 1,115 2,008 1,913 Total revenues 98,855 92,903 198,651 184,834 Operating costs: Medical costs 65,458 60,268 131,193 120,113 Operating costs 13,162 13,809 27,239 27,434 Cost of products sold 11,340 9,748 22,396 19,153 Depreciation and amortization 1,020 1,021 2,017 1,991 Total operating costs 90,980 84,846 182,845 168,691 Earnings from operations 7,875 8,057 15,806 16,143 Interest expense ( 985 ) ( 828 ) ( 1,829 ) ( 1,582 ) Loss on sale of subsidiary and subsidiaries held for sale ( 1,225 ) \u2014 ( 8,311 ) \u2014 Earnings before income taxes 5,665 7,229 5,666 14,561 Provision for income taxes ( 1,244 ) ( 1,572 ) ( 2,466 ) ( 3,130 ) Net earnings 4,421 5,657 3,200 11,431 Earnings attributable to noncontrolling interests ( 205 ) ( 183 ) ( 393 ) ( 346 ) Net earnings attributable to UnitedHealth Group common shareholders $ 4,216 $ 5,474 $ 2,807 $ 11,085 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 4.58 $ 5.89 $ 3.05 $ 11.91 Diluted $ 4.54 $ 5.82 $ 3.02 $ 11.77 Basic weighted-average number of common shares outstanding 921 930 921 931 Dilutive effect of common share equivalents 7 10 8 11 Diluted weighted-average number of common shares outstanding 928 940 929 942 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 8 7 7 6 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2024 2023 2024 2023 Net earnings $ 4,421 $ 5,657 $ 3,200 $ 11,431 Other comprehensive income (loss): Gross unrealized (losses) gains on investment securities during the period ( 75 ) ( 431 ) ( 365 ) 209 Income tax effect 17 99 85 ( 48 ) Total unrealized (losses) gains, net of tax ( 58 ) ( 332 ) ( 280 ) 161 Gross reclassification adjustment for net realized gains included in net earnings ( 26 ) ( 47 ) ( 58 ) ( 34 ) Income tax effect 6 11 13 8 Total reclassification adjustment, net of tax ( 20 ) ( 36 ) ( 45 ) ( 26 ) Foreign currency translation gains (losses) 8 267 ( 285 ) 608 Reclassification adjustment for translation losses included in net earnings 86 \u2014 4,214 \u2014 Total foreign currency translation gains 94 267 3,929 608 Other comprehensive income (loss) 16 ( 101 ) 3,604 743 Comprehensive income 4,437 5,556 6,804 12,174 Comprehensive income attributable to noncontrolling interests ( 205 ) ( 183 ) ( 393 ) ( 346 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 4,232 $ 5,373 $ 6,411 $ 11,828 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 Net earnings 4,216 158 4,374 Other comprehensive (loss) income ( 78 ) 94 16 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 210 210 Common share repurchases \u2014 \u2014 3 1 4 Cash dividends paid on common shares ($ 2.10 per share) ( 1,935 ) ( 1,935 ) Redeemable noncontrolling interests fair value and other adjustments ( 36 ) ( 36 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 338 ) ( 338 ) Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2024 921 $ 9 $ 373 $ 92,400 $ ( 2,296 ) $ ( 1,127 ) $ 5,317 $ 94,676 Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 Net earnings 5,474 139 5,613 Other comprehensive (loss) income ( 368 ) 267 ( 101 ) Issuances of common stock, and related tax effects 1 \u2014 218 218 Share-based compensation 232 232 Common share repurchases ( 6 ) \u2014 ( 442 ) ( 2,585 ) ( 3,027 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,747 ) ( 1,747 ) Redeemable noncontrolling interests fair value and other adjustments ( 8 ) ( 8 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 478 478 Distribution to nonredeemable noncontrolling interests ( 111 ) ( 111 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2024 924 $ 9 $ \u2014 $ 95,774 $ ( 1,971 ) $ ( 5,056 ) $ 5,665 $ 94,421 Net earnings 2,807 307 3,114 Other comprehensive (loss) income ( 325 ) 3,929 3,604 Issuances of common stock, and related tax effects 3 \u2014 438 438 Share-based compensation 562 562 Common share repurchases ( 6 ) \u2014 ( 571 ) ( 2,517 ) ( 3,088 ) Cash dividends paid on common shares ($ 3.98 per share) ( 3,664 ) ( 3,664 ) Redeemable noncontrolling interests fair value and other adjustments ( 56 ) ( 56 ) Acquisition and other adjustments\n) $ 14,561 16 Table of Contents ITEM\u00a02.",
      "score": 0.9985
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 701 $ 592 $ (3,634) $ (7,939) 1 351 296 (1,869) (4,329) (1) (351) (279) 1,959 5,239 (2) (701) (557) 3,989 11,641 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 701 $ 592 $ (3,634) $ (7,939) 1 351 296 (1,869) (4,329) (1) (351) (279) 1,959 5,239 (2) (701) (557) 3,989 11,641 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    },
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    },
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect to continue to incur direct response costs and experience business disruption impacts over the remainder of the year, including costs to continue to restore Change Healthcare\u2019s services.",
    "We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs."
  ],
  "curated_text": "Symbol: UNH. Year: 2024. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 26,286 $ 25,427 Short-term investments 5,037 4,201 Accounts receivable, net 23,115 21,276 Other current receivables, net 26,762 17,694 Assets under management 3,414 3,755 Prepaid expenses and other current assets 7,424 6,084 Total current assets 92,038 78,437 Long-term investments 46,113 47,609 Property, equipment and capitalized software, net 9,801 11,450 Goodwill 105,436 103,732 Other intangible assets, net 14,729 15,194 Other assets 17,939 17,298 Total assets $ 286,056 $ 273,720 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 32,547 $ 32,395 Accounts payable and accrued liabilities 30,886 31,958 Short-term borrowings and current maturities of long-term debt 11,371 4,274 Unearned revenues 2,572 3,355 Other current liabilities 27,294 27,072 Total current liabilities 104,670 99,054 Long-term debt, less current maturities 63,727 58,263 Deferred income taxes 3,631 3,021 Other liabilities 14,794 14,463 Total liabilities 186,822 174,801 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,558 4,498 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 921 and 924 issued and outstanding 9 9 Additional paid-in capital 373 \u2014 Retained earnings 92,400 95,774 Accumulated other comprehensive loss ( 3,423 ) ( 7,027 ) Nonredeemable noncontrolling interests 5,317 5,665 Total equity 94,676 94,421 Total liabilities, redeemable noncontrolling interests and equity $ 286,056 $ 273,720 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2024 2023 2024 2023 Revenues: Premiums $ 76,897 $ 72,474 $ 154,885 $ 145,260 Products 12,211 10,651 24,120 20,918 Services 8,750 8,663 17,638 16,743 Investment and other income 997 1,115 2,008 1,913 Total revenues 98,855 92,903 198,651 184,834 Operating costs: Medical costs 65,458 60,268 131,193 120,113 Operating costs 13,162 13,809 27,239 27,434 Cost of products sold 11,340 9,748 22,396 19,153 Depreciation and amortization 1,020 1,021 2,017 1,991 Total operating costs 90,980 84,846 182,845 168,691 Earnings from operations 7,875 8,057 15,806 16,143 Interest expense ( 985 ) ( 828 ) ( 1,829 ) ( 1,582 ) Loss on sale of subsidiary and subsidiaries held for sale ( 1,225 ) \u2014 ( 8,311 ) \u2014 Earnings before income taxes 5,665 7,229 5,666 14,561 Provision for income taxes ( 1,244 ) ( 1,572 ) ( 2,466 ) ( 3,130 ) Net earnings 4,421 5,657 3,200 11,431 Earnings attributable to noncontrolling interests ( 205 ) ( 183 ) ( 393 ) ( 346 ) Net earnings attributable to UnitedHealth Group common shareholders $ 4,216 $ 5,474 $ 2,807 $ 11,085 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 4.58 $ 5.89 $ 3.05 $ 11.91 Diluted $ 4.54 $ 5.82 $ 3.02 $ 11.77 Basic weighted-average number of common shares outstanding 921 930 921 931 Dilutive effect of common share equivalents 7 10 8 11 Diluted weighted-average number of common shares outstanding 928 940 929 942 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 8 7 7 6 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2024 2023 2024 2023 Net earnings $ 4,421 $ 5,657 $ 3,200 $ 11,431 Other comprehensive income (loss): Gross unrealized (losses) gains on investment securities during the period ( 75 ) ( 431 ) ( 365 ) 209 Income tax effect 17 99 85 ( 48 ) Total unrealized (losses) gains, net of tax ( 58 ) ( 332 ) ( 280 ) 161 Gross reclassification adjustment for net realized gains included in net earnings ( 26 ) ( 47 ) ( 58 ) ( 34 ) Income tax effect 6 11 13 8 Total reclassification adjustment, net of tax ( 20 ) ( 36 ) ( 45 ) ( 26 ) Foreign currency translation gains (losses) 8 267 ( 285 ) 608 Reclassification adjustment for translation losses included in net earnings 86 \u2014 4,214 \u2014 Total foreign currency translation gains 94 267 3,929 608 Other comprehensive income (loss) 16 ( 101 ) 3,604 743 Comprehensive income 4,437 5,556 6,804 12,174 Comprehensive income attributable to noncontrolling interests ( 205 ) ( 183 ) ( 393 ) ( 346 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 4,232 $ 5,373 $ 6,411 $ 11,828 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 Net earnings 4,216 158 4,374 Other comprehensive (loss) income ( 78 ) 94 16 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 210 210 Common share repurchases \u2014 \u2014 3 1 4 Cash dividends paid on common shares ($ 2.10 per share) ( 1,935 ) ( 1,935 ) Redeemable noncontrolling interests fair value and other adjustments ( 36 ) ( 36 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 338 ) ( 338 ) Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2024 921 $ 9 $ 373 $ 92,400 $ ( 2,296 ) $ ( 1,127 ) $ 5,317 $ 94,676 Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 Net earnings 5,474 139 5,613 Other comprehensive (loss) income ( 368 ) 267 ( 101 ) Issuances of common stock, and related tax effects 1 \u2014 218 218 Share-based compensation 232 232 Common share repurchases ( 6 ) \u2014 ( 442 ) ( 2,585 ) ( 3,027 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,747 ) ( 1,747 ) Redeemable noncontrolling interests fair value and other adjustments ( 8 ) ( 8 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 478 478 Distribution to nonredeemable noncontrolling interests ( 111 ) ( 111 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2024 924 $ 9 $ \u2014 $ 95,774 $ ( 1,971 ) $ ( 5,056 ) $ 5,665 $ 94,421 Net earnings 2,807 307 3,114 Other comprehensive (loss) income ( 325 ) 3,929 3,604 Issuances of common stock, and related tax effects 3 \u2014 438 438 Share-based compensation 562 562 Common share repurchases ( 6 ) \u2014 ( 571 ) ( 2,517 ) ( 3,088 ) Cash dividends paid on common shares ($ 3.98 per share) ( 3,664 ) ( 3,664 ) Redeemable noncontrolling interests fair value and other adjustments ( 56 ) ( 56 ) Acquisition and other adjustments\n) $ 14,561 16 Table of Contents ITEM\u00a02. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 701 $ 592 $ (3,634) $ (7,939) 1 351 296 (1,869) (4,329) (1) (351) (279) 1,959 5,239 (2) (701) (557) 3,989 11,641 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 701 $ 592 $ (3,634) $ (7,939) 1 351 296 (1,869) (4,329) (1) (351) (279) 1,959 5,239 (2) (701) (557) 3,989 11,641 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. Top negative sentences: It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations. It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations. It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations. Forward-looking snippets: Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We expect to continue to incur direct response costs and experience business disruption impacts over the remainder of the year, including costs to continue to restore Change Healthcare\u2019s services. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. We will continue seeking to balance growth and profitability across all these dimensions. We expect broad-based competition to continue as the industry adapts to individual and employer needs."
}